Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stalemate for S&N, Kinetic patent row

This article was originally published in Clinica

Executive Summary

Smith & Nephew's ongoing patent row with wound care rival Kinetic Concepts reached another milestone this week when the US Court of Appeals upheld a previous ruling that gave S&N the all-clear to market its gauze-based negative pressure wound therapy (NPWT) products. The court found that S&N's Versatile 1 system, which the company gained through its acquisition of BlueSky Medical, did not infringe Kinetic's Wake Forest patents. However, this favourable ruling for S&N was tempered by another verdict which stated that two of Kinetic's patents were valid and enforceable. Investors welcomed the court's affirmation of Kinetic's technology by boosting the San Antonio, California firm's stock value – Kinetic shares climbed 8% to close at $26.06 on February 2. The two companies are also embroiled in litigation relating to S&N's foam-based NPWT products. In January, the UK patent court banned S&N temporarily from selling these foam dressings in the UK until a trial date is set (see Clinica No 1332, p 19).

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

MT041941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel